Table 4.

Haematological parameters in different treatment groups

No.	Group	Hb,g/L	Total RBC as 1012/L	PCV, L/L	MCV, fL	MCH, pg	MCHC, g/L	RDW, %	Total WBC as 109/L	N, %	L, %	M, %	E, %	B, %	Plts as 109/L
1	Untreated	121 ± 1.0	7.91 ± 0.9	0.36 ± 0.0	46 ± 1.5	15 ± 0.7	332 ± 1.1	20.6 ± 1.0	5.8 ± 1.3	37 ± 1.0	55 ± 1.1	5 ± 0.8	2 ± 0.1	1 ± 0.0	790 ± 1.2
2	Gemcitabine (10 mg/kg per 3 d)	118 ± 1.4	7.60 ± 1.1	0.38 ± 0.0	50.0 ± 1.8	16.0 ± 0.6	313 ± 1.8	22.1 ± 0.7	6.0 ± 1.2	33.0 ± 1.2	60.0 ± 0.7	6.0 ± 1.3	1.0 ± 0.1	0.0 ± 0.1	720 ± 1.4
3	O.s (200 mg/kg per day)	118 ± 1.5	8.0 ± 0.8	0.38 ± 0.0	48.0 ± 2.0	15.0 ± 1.1	307 ± 0.9	22.3 ± 1.6	6.10 ± 0.7	35.0 ± 0.8	53.0 ± 0.6	9.0 ± 1.0	1.0 ± 0.1	2.0 ± 0.0	801 ± 0.8
4	O.s (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination	115 ± 1.7	7.1 ± 1.4	0.35 ± 0.0	50.0 ± 1.6	16.0 ± 0.7	321 ± 1.5	21.5 ± 0.8	5.70 ± 1.5	32.0 ± 0.9	60.0 ± 1.1	5.0 ± 0.7	2.0 ± 0.1	1.0 ± 0.1	760 ± 0.9
5	O.s (400 mg/kg per day)	123 ± 1.6	7.9 ± 0.7	0.36 ± 0.0	46.0 ± 1.5	16.0 ± 1.6	335 ± 2.0	21.0 ± 0.9	5.70 ± 1.8	33.0 ± 1.2	61.0 ± 1.2	4.0 ± 0.6	2.0 ± 0.1	0.0 ± 0.0	740 ± 1.0
6	O.s (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination	123 ± 1.1	7.70 ± 0.9	0.36 ± 0.0	47.0 ± 1.2	16.0 ± 0.4	331 ± 1.2	22.6 ± 1.3	6.0 ± 1.5	30.0 ± 0.9	60.0 ± 1.1	8.0 ± 1.3	1.0 ± 0.1	1.0 ± 0.0	810 ± 1.3

Results are expressed as mean ± SD (n = 6). The P values in all treated groups were insignificant compared to the untreated group. No statistical difference was also observed among all treatment groups using two-way ANOVA and Tukey’s honest significant difference posthoc test. B: Basophile; E: Eosinophile; Hb: Haemoglobin; L: Lymphocyte; M: Monocyte; MCH: Mean cell haemoglobin; MCHC: Mean cell haemoglobin concentration; MCV: Mean cell volume; N: Neutrophile; O.s: Orthosiphon stamineus; PCV: Packed cell volume; Plts: Platelets; RBC: Red blood cells; RDW: Red cell distribution width; WBC: White blood cells.